Related Tags >> FDA infectious diseases Phase III ceftobiprole

MRSA News

Most Popular MRSA Story

FDA to review Theravance's telavancin response

March 6, 2008 — 7:59am ET

More news in Theravance's ongoing battle to win approval for its antibiotic telavancin: the FDA has accepted the company's response to the Read more...

MRSA Press Releases

PRESS RELEASE: Scientists Identify Factor Key to Severity of Community-Associated Methicillin-Resistant Staph Infections
PRESS RELEASE: CDC estimates 94,000 invasive drug-resistant staph infections occurred in the U.S. in 2005

Latest Headlines

FDA: Targanta must conduct new oritavancin study
December 9, 2008
Basilea shares plunge on antibiotic delay
March 18, 2008
Cepheid cashes in on MRSA trends--for now
March 7, 2008
FDA to review Theravance's telavancin response
March 6, 2008
FDA cancels meeting as hopes rise for Basilea
February 13, 2008
ALSO NOTED: Ventana and Roche forge confidentiality agreement; Rigel wins $3M payment; and much more...
November 14, 2007
Dry antibiotic pipeline concerns infectious disease experts
November 5, 2007
Basilea reports positive Phase III antibiotic data
October 9, 2007
WHO: Infectious disease a growing threat
August 24, 2007

Paid Research Reports

More Research Reports >>